Novo Nordisk A/s share price today

(NVO)

Novo Nordisk A/s share price is $108.82 & ₹9,220.32 as on 6 Dec 2024, 2.30 'hrs' IST

$108.82

▲

-0.15

(-0.14%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Novo Nordisk A/s share price in Dollar and Rupees. Guide to invest in Novo Nordisk A/s from India. Also see the sentimental analysis on Indian investors investing in Novo Nordisk A/s. Get details on the Indian mutual funds that are investing in Novo Nordisk A/s. Get Analyst recommendations and forecasts along with all the Novo Nordisk A/s's financials.

Novo Nordisk A/s share price movements

$108.23
$109.26
$108.82
0.54%
Downside
Day's Volatility :0.94%
Upside
0.4%
$94.73
$148.15
$108.82
12.95%
Downside
52 Weeks Volatility :36.06%
Upside
26.55%

Novo Nordisk A/s Returns

Period	Novo Nordisk A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.13%	-4.4%	0.0%
6 Months	-23.94%	0.6%	0.0%
1 Year	12.25%	11.5%	0.0%
3 Years	97.29%	12.2%	-19.7%

Novo Nordisk A/s Key Statistics

in dollars & INR

Previous Close	$108.97
Open	$108.62
Today's High	$109.26
Today's Low	$108.23
Market Capitalization	$472.8B
Today's Volume	$4.9M
52 Week High	$148.15
52 Week Low	$94.7313
Revenue TTM	$270.6B
EBITDA	$127.4B
Earnings Per Share (EPS)	$2.99
PE Ratio	34.03
Dividend Yield	1.42%
Profit Margin	35.01%
Quarterly Earnings Growth YOY	0.22%
Return On Equity TTM	88.73%

How to invest in Novo Nordisk A/s from India?

It is very easy for Indian residents to invest directly in Novo Nordisk A/s from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novo Nordisk A/s stock in both rupees (INR) and dollars (USD). Search for Novo Nordisk A/s or NVO on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novo Nordisk A/s or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novo Nordisk A/s shares which would translate to 0.008 fractional shares of Novo Nordisk A/s as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Novo Nordisk A/s

39.83%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Investment in Novo Nordisk A/s from India has grown in the last 30 days as on Dec 6, 2024. 39.83% more purchase transactions for Novo Nordisk A/s in the last 30 days versus the previous period.

88%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Novo Nordisk A/s on INDmoney from India has grown in the last 30 days as on Dec 6, 2024. 88% more investors are searching Novo Nordisk A/s in the last 30 days versus the previous period.

Indian Mutual Funds that own Novo Nordisk A/s

Name	Shares Held	Change in Shares	% of Assets
Axis Innovation Fund Direct Growth	8068	-440.27	0.62%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	4514	-2021.73	2.71%

Global Institutional Holdings in Novo Nordisk A/s

Jennison Associates LLC
0.45%
FMR Inc
0.40%
Morgan Stanley - Brokerage Accounts
0.32%
Bank of America Corp
0.32%
Fisher Asset Management, LLC
0.30%
Fayez Sarofim & Company
0.28%

Analyst Recommendation on Novo Nordisk A/s

Buy

62%Buy

31%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novo Nordisk A/s(by analysts ranked 0 to 5 stars)

Based on 32 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novo Nordisk A/s

What analysts predicted

Upside of 765.02%

Current:

$108.82

Target:

$941.31

Insights on Novo Nordisk A/s

Increasing Revenue
Novo Nordisk A/S has shown consistent revenue growth over the last three quarters. The company's revenue increased from $65.34 billion to $71.31 billion, representing an average growth of 4.3% each quarter.
Increasing Net Profit
Novo Nordisk A/s has shown consistent profit growth over the last two quarters. Their net profit increased from $20.05 billion to $27.30 billion, marking an average rise of 26.6% per quarter.
Vs LLY
In the last 1 year, Eli Lilly And Company has given 35.7% return, outperforming this stock by 24.3%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 224.7% return, outperforming this stock by 123.0%

Novo Nordisk A/s Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$17.0B	↑ 0.12%
Net Income	$5.9B	↑ 1.31%
Net Profit Margin	34.54%	↑ 0.4%

	FY19	Y/Y Change
Revenue	$18.1B	↑ 9.11%
Net Income	$5.8B	↑ 0.84%
Net Profit Margin	31.92%	↓ 2.62%

	FY20	Y/Y Change
Revenue	$20.7B	↑ 4.04%
Net Income	$6.9B	↑ 8.18%
Net Profit Margin	33.19%	↑ 1.27%

	FY21	Y/Y Change
Revenue	$21.4B	↑ 10.91%
Net Income	$7.3B	↑ 13.33%
Net Profit Margin	33.92%	↑ 0.73%

	FY22	Y/Y Change
Revenue	$25.2B	↑ 25.68%
Net Income	$7.9B	↑ 16.27%
Net Profit Margin	31.38%	↓ 2.54%

	FY23	Y/Y Change
Revenue	$34.0B	↑ 31.26%
Net Income	$12.3B	↑ 50.71%
Net Profit Margin	36.03%	↑ 4.65%

	Q2 FY23	Q/Q Change
Revenue	$7.9B	↑ 1.75%
Net Income	$2.8B	↓ 1.95%
Net Profit Margin	35.78%	↓ 1.35%

	Q3 FY23	Q/Q Change
Revenue	$8.4B	↑ 8.16%
Net Income	$3.2B	↑ 15.7%
Net Profit Margin	38.27%	↑ 2.49%

	Q4 FY23	Q/Q Change
Revenue	$9.6B	↑ 12.14%
Net Income	$3.2B	↓ 2.29%
Net Profit Margin	33.35%	↓ 4.92%

	Q1 FY24	Q/Q Change
Revenue	$9.5B	↓ 0.78%
Net Income	$3.7B	↑ 15.68%
Net Profit Margin	38.88%	↑ 5.53%

	Q2 FY24	Q/Q Change
Revenue	$9.8B	↑ 4.15%
Net Income	$2.9B	↓ 21.08%
Net Profit Margin	29.46%	↓ 9.42%

	Q3 FY24	Q/Q Change
Revenue	$71.3B	↑ 4.78%
Net Income	$27.3B	↑ 36.16%
Net Profit Margin	38.28%	↑ 8.82%

	FY18	Y/Y Change
Total Assets	$16.9B	↑ 8.22%
Total Liabilities	$9.0B	↑ 12.16%

	FY19	Y/Y Change
Total Assets	$18.7B	↑ 13.4%
Total Liabilities	$10.1B	↑ 15.42%

	FY20	Y/Y Change
Total Assets	$23.7B	↑ 15.37%
Total Liabilities	$13.3B	↑ 19.96%

	FY21	Y/Y Change
Total Assets	$29.6B	↑ 34.22%
Total Liabilities	$18.8B	↑ 51.67%

	FY22	Y/Y Change
Total Assets	$34.3B	↑ 24.03%
Total Liabilities	$22.4B	↑ 27.48%

	FY23	Y/Y Change
Total Assets	$46.1B	↑ 30.35%
Total Liabilities	$30.5B	↑ 31.79%

	Q2 FY23	Q/Q Change
Total Assets	$40.9B	↑ 12.29%
Total Liabilities	$27.7B	↑ 11.83%

	Q3 FY23	Q/Q Change
Total Assets	$43.0B	↑ 6.89%
Total Liabilities	$29.7B	↑ 8.84%

	Q4 FY23	Q/Q Change
Total Assets	$46.1B	↑ 4.79%
Total Liabilities	$30.5B	↑ 0.39%

	Q1 FY24	Q/Q Change
Total Assets	$43.6B	↓ 4.95%
Total Liabilities	$29.2B	↓ 3.81%

	Q2 FY24	Q/Q Change
Total Assets	$53.3B	↑ 23.57%
Total Liabilities	$37.1B	↑ 28.42%

	Q3 FY24	Q/Q Change
Total Assets	$397.4B	↑ 7.6%
Total Liabilities	$276.9B	↑ 7.81%

	FY18	Y/Y Change
Operating Cash Flow	$6.8B	↑ 8.38%
Investing Cash Flow	$-1.8B	↑ 83.84%
Financing Cash Flow	$-5.3B	↓ 3.27%

	FY19	Y/Y Change
Operating Cash Flow	$7.0B	↑ 4.85%
Investing Cash Flow	$-1.7B	↓ 4.73%
Financing Cash Flow	$-5.3B	↑ 2.79%

	FY20	Y/Y Change
Operating Cash Flow	$8.5B	↑ 11.05%
Investing Cash Flow	$-3.7B	↑ 94.94%
Financing Cash Flow	$-5.3B	↓ 9.13%

	FY21	Y/Y Change
Operating Cash Flow	$8.4B	↑ 5.87%
Investing Cash Flow	$-4.8B	↑ 40.87%
Financing Cash Flow	$-3.9B	↓ 20.94%

	FY22	Y/Y Change
Operating Cash Flow	$11.2B	↑ 43.43%
Investing Cash Flow	$-3.5B	↓ 21.16%
Financing Cash Flow	$-7.4B	↑ 103.18%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$4.2B	↓ 4.15%
Investing Cash Flow	$-2.3B	↑ 139.69%
Financing Cash Flow	$-1.8B	↓ 38.95%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$5.9B	↑ 43.35%
Investing Cash Flow	$-4.2B	↑ 83.12%
Financing Cash Flow	$-2.8B	↑ 57.53%

Novo Nordisk A/s Technicals Summary

Sell

Neutral

Buy

Novo Nordisk A/s is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Novo Nordisk A/s Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novo Nordisk A/s	3.14%	-23.94%	12.25%	97.29%	283.38%
Eli Lilly And Company	3.02%	-5.9%	35.96%	226.3%	565.17%
Johnson & Johnson	-1.95%	5.25%	-0.39%	-5.24%	10.18%
Merck & Co. Inc.	-0.12%	-23.0%	-3.15%	39.19%	13.4%
Abbvie Inc	-9.66%	7.29%	22.84%	49.59%	110.28%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novo Nordisk A/s	34.03	34.03	1.59	22.7	0.89	0.21	0.01	27.07
Eli Lilly And Company	85.43	85.43	0.75	13.16	0.65	0.14	0.01	15.83
Johnson & Johnson	25.65	25.65	0.92	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	21.26	21.26	0.07	7.75	0.28	0.11	0.03	17.58
Abbvie Inc	63.74	63.74	0.44	10.93	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novo Nordisk A/s	Buy	$472.8B	283.38%	34.03	35.01%
Eli Lilly And Company	Buy	$715.3B	565.17%	85.43	20.48%
Johnson & Johnson	Buy	$373.6B	10.18%	25.65	16.74%
Merck & Co. Inc.	Buy	$260.9B	13.4%	21.26	19.23%
Abbvie Inc	Buy	$323.5B	110.28%	63.74	9.22%

Novo Nordisk A/s Dividend announcements

Novo Nordisk A/s Dividends September, 2024
In the quarter ending September,2024. Novo Nordisk A/s has declared dividend of $0.51
Read More

About Novo Nordisk A/s

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.

Organization	Novo Nordisk A/s
Employees	71880
CEO	Mr. Lars Fruergaard Jorgensen
Industry	Health Technology

Management People of Novo Nordisk A/s

Name	Title
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board

Important FAQs about investing in Novo Nordisk A/s from India :

What is Novo Nordisk A/s share price today?

Novo Nordisk A/s (NVO) share price today is $108.82.

Can Indians buy Novo Nordisk A/s shares?

Yes, Indians can invest in the Novo Nordisk A/s (NVO) from India.

With INDmoney, you can buy Novo Nordisk A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novo Nordisk A/s at zero transaction cost.

How can I buy Novo Nordisk A/s shares from India?

It is very easy to buy Novo Nordisk A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novo Nordisk A/s be purchased?

Yes, you can buy fractional shares of Novo Nordisk A/s with INDmoney app.

What are the documents required to start investing in Novo Nordisk A/s stocks?

To start investing in Novo Nordisk A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.